The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
NCT ID: NCT05718401
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2022-11-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
NCT01018927
Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis
NCT04862273
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
NCT07216469
Molecular Imaging of Primary Amyloid Cardiomyopathy
NCT02641145
A Study Of MCG In Cardiac Amyloidosis
NCT07218705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To investigate the clinical features, risk factors and prognosis of patients with multiple myeloma myocardial amyloidosis. The clinical experience of diagnosis and treatment of this complication was summarized. On this basis, a standard database suitable for the northwest population was established based on NMR phenoomics, and a hierarchical diagnostic model (1-2-3-4) was explored for multiple myeloma patients with myocardial amyloidosis, and the prognosis was evaluated simultaneously. In order to establish an early, non-invasive, sensitive and quantitative diagnostic model for multiple myeloma complicated with myocardial amyloidosis, and to provide clinical basis for further research on early diagnosis, early prevention and early treatment of the disease. To provide the basis for individualized stratified prevention and treatment of patients with multiple myeloma myocardial amyloidosis, reduce the family medical burden and related side effects, improve the quality of life of patients with myeloma myocardial amyloidosis, prolong the survival period, and improve the cure rate
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Patients With Multiple Myeloma Myocardial Amyloidosis
NMR
nuclear magnetic resonance in genomics
Control group
Patients With Multiple Myeloma but without Myocardial Amyloidosis.
NMR
nuclear magnetic resonance in genomics
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NMR
nuclear magnetic resonance in genomics
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liu huasheng, Ph.D
Role: STUDY_DIRECTOR
First Hospital of Xi'an Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Xian Jiaotong University
Xi’an, Shanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XJTU1AF-CRF-2022-033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.